Generic Name and Formulations:
Tazarotene 0.1%; crm.
Indications for AVAGE:
Adjunct to comprehensive skin care and sunlight avoidance programs in the palliation of facial fine wrinkles, facial mottled hyper- and hypopigmentation, and facial benign lentigines.
Limitations Of use:
Does not eliminate or prevent wrinkles or restore more youthful skin. Does not reverse photoaging or repair sun damaged skin; does not mitigate coarse or deep wrinkling, tactile roughness, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. The safety and effectiveness for the prevention or treatment of actinic keratoses, skin neoplasms, or lentigo maligna have not been established.
≥17yrs: apply thin film to entire face once daily in the PM. Females of reproductive potential: begin therapy during normal menses.
<17yrs: not established.
Assess any facial pigmented lesions (eg, lentigo maligna) prior to initiation. Obtain reliable negative pregnancy test within 2 weeks prior to therapy. Females of reproductive potential should use effective contraception. Do not use on broken, eczematous, or sunburned skin. Sun sensitivity. Avoid eyes, mouth, sun, and UV light. Increased irritation in extreme weather. Discontinue or reduce dose frequency if excessive irritation occurs. Nursing mothers.
Avoid use until the effects of strong drying agents have subsided. Avoid concomitant with photosensitizers or other irritants.
Desquamation, erythema, burning, dry or irritation skin, pruritus, irritant contact dermatitis, stinging, rash, cheilitis.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry
- Medical Schools Phase Out Lectures as Education Shifts Outside the Classroom
- Clonidine Testing Is Safe and Reliable for Diagnosing Growth Hormone Deficiency